/
Other
Safety and Efficacy
147
Pipeline Programs↗
182
Active Trials↗
324
Companies Involved↗
Safety and Efficacy is a highly competitive landscape with 147 programs across 324 companies. The most active players are A2 Biotherapeutics Inc., Gilead, AstraZeneca. 36 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical20
Phase 120
Phase 271
Phase 336
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
100 of 126 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 126 classified programs, each share of the total. Modality classified for 100% of 147 pipeline programs.
Analysis
Trial Status
1,706
clinical trials
Completed1,104 · 65%
Unknown status182 · 11%
Terminated169 · 10%
Recruiting105 · 6%
Withdrawn58 · 3%
Active, not recruiting45 · 3%
Other43 · 3%
Clinical Trials
Trial Activity
1706 trials
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT
Recruiting·—·Phase 1·NCT06558253·12 enrolled
Metformin in Safety and Efficacy in Gouty Patients
Recruiting·—·Phase 2·NCT06924658·70 enrolled
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Recruiting·—·Phase 2·NCT06741722·20 enrolled
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Recruiting·—·Phase 2·NCT05695261·37 enrolled
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Recruiting·—·Phase 1·NCT06120166·18 enrolled
Page 1 of 114
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)